A cell-permeable, all-D-amino acid autophagy-inducing peptide based on the retro-inverso sequence of Tat-Beclin1 (Cat. No. 506048) that is expected to be more resistant to proteolytic degradation than Tat-Beclin1 and is shown to be more potent than Tat-Beclin1 in inducing autophagy in muscle, heart, and pancreas tissues in 6-wk-old GFP-LC3 transgenic mice (1.94-, 1.48-, and 1.16-fold of Tat-Beclin1 GFP-LC3 induction potency in respective tissue in 6 h; 20 mg/kg i.p.) in vivo. Only the retro-inverso peptide, but not Tat-Beclin1, is effective in reducing autophagy substrate p62 level in the brain tissue of 5-d-old neontal GFP-LC3 mice (20 mg/kg i.p.). The retro-inverso peptide treatment is also reported to greatly reduce brain viral titre in neonatal mice subjected to WNV (West Nile Virus) CNS (central nervous system) infection (>1000-fold reduction 6 d post infection; 20 mg/kg/d i.p. beginning 1 d post infection), while being ineffective against WNV CNS infection in mice with monoallelic deletion of the Beclin1 gene Becn1.
5 mg in Glass bottle
Packaged under inert gas
Cell permeable: yes
Toxicity: Standard Handling (A)
Supplied as a trifluoroacetate salt.
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Shoji-Kawata, S., et al. 2013. Nature.494, 201.
Sold under license of US Patent 8,722,628.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany